A CRITICAL APPRAISAL OF COVID-19 IN INDIA

Authors

  • Dr Pradip Kumar Das Jagannath Kishore College,Purulia under Sidho-Kanho-Birsha University,Purulia

DOI:

https://doi.org/10.14738/abr.85.8271

Keywords:

COVID-19; India; Healthcare; Strategies; Community hospital.

Abstract

COVID-19 virus causes respiratory problems including pneumonia, cold, sneezing and coughing, and  transmits human to human or human to animal via airborne droplets. World Health Organization advises to avoid public gatherings and close contact to infected persons and pet animals. India has made several precautionary measures to mitigate the disease at the initial stage. However, the density of population in India makes it difficult to control the disease, if government does not incorporate the visionary strategies. Since attacked several nations have been worried for their people lives, developing country like India with huge population should consider about the livelihood of the people belonging to below poverty line or BPL equally with other life. This paper will give insights to make effective strategy to culminate the world threat COVID-19 in India.

Keywords: COVID-19; India; Healthcare; Strategies; Community hospital.

Author Biography

Dr Pradip Kumar Das, Jagannath Kishore College,Purulia under Sidho-Kanho-Birsha University,Purulia

Associate professor&Teacher-in-Charge,Commerce Unit,
J.K.College,Purulia

References

[1] Coronavirus COVID-19 Global Cases by the Center for Systems Science andEngineering(CSSE).AccessedMarch23,2020,https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6.
[2] WHO. India ramps up efforts to contain the spread of novel coronavirus. AccessedMarch23,2020,https://www.who.int/india/emergencies/novelcoronavirus-2020.
[3] R. Lu, X. Zhao, J. Li, P. Niu, B. Yang, H. Wu, et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet, (2020),http://dx.doi.org/10.1016/S0140-6736(20)30251-8.
[4] C. Rothe, M. Schunk, P. Sothmann, G. Bretzel, G. Froeschl, C. Wallrauch, et al.Transmission of 2019-nCoV infection from an asymptomatic contact in Germany.N Engl J Med, (2020),http://dx.doi.org/10.1056/NEJMc2001468
[5] K. Kupferschmidt. Study claiming new coronavirus can be transmitted by people without symptoms was flawed. Science, (2020), http://dx.doi.org/1o.1126/science.abb1524.
[6] Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A Novel Corona virus from Patients with Pneumonia in China, 2019. 24 January 2020. New England Journal of Medicine.
[7] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 24 January 2020.
[8] Chan JF-W, Yuan S, Kok K-H, To KK-W, Chu H, Yang J, et al. A familial cluster of pneumonia associated with the 2019 novel corona virus indicating person-to-person transmission: a study of a family cluster. The Lancet. 24 January 2020.
[9] Ministerio de Sanidad. Neumonía por un nuevo coronavirus (2019-nCov) en China [accessed 4 Feb 2020]. Available from: https://www.mscbs.gob.es/profesionales/saludPublica/ccayes/alertasActual/nCov-China/home.htm.
[10] European Centre for Disease Prevention and Control (ECDC). Novel coronavirus [accessed 4 Feb 2020].Available from: https://www.ecdc.europa.eu/en/novel-corona virus-china.
[11] Centers for Disease Control and Prevention (CDC). 2019 Novel Coronavirus [accessed 4 Feb 2020]. Available from: https://www.cdc.gov/corona virus/2019-ncov/index.html.
[12] OMS. Corona virus[accessed4 Feb 2020].Available from: https://www.who.int/es/health-topics/coronavirus/coronavirua.
[13] Zhao Z, Zhang F, Xu M, Huang K, Zhong W, Cai W, et al. Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China. J Med Microbiol. 2003;52:715–20.
[14] Chan JF, Chan KH, Kao RY, To KK, Zheng BJ, Li CP, et al. Broadspectrum antivirals for the emerging Middle East respiratory syndrome coronavirus. J Inf Secur. 2013;67:606–16.
[15] Al-Tawfiq JA, Momattin H, Dib J, Memish ZA. Ribavirin and interferon therapy in patients infected with the Middle Eastrespiratory syndrome corona virus: an observational study. Int J Infect Dis. 2014;20:42–6.
[16] Al-Qahtani AA, Lyroni K, Aznaourova M, Tseliou M, Al-Anazi MR, Al-Ahdal MN, et al. Middle East respiratory syndrome corona virus spike glycoprotein suppresses macrophage responses via DPP4-mediated induction of IRAK-M and PPARγ. Oncotarget. 2017;8(6):9053–66. doi:10.18632/oncotarget.14754.
[17] Bin Saeed AA, Abedi GR, Alzahrani AG, Salameh I, AbdirizakF, Alhakeem R, et al. Surveillance and testing for Middle East respiratory syndrome Coronavirus, Saudi Arabia, April 2015–February 2016. Emerg Infect Dis. 2017;23(4):682–5. doi:10.3201/eid2304.161793.
[18] Arabi YM, Balkhy HH, Hayden FG, Bouchama A, Luke T, Baillie JK, et al. Middle East respiratory syndrome. N Engl J Med. 2017;376(6):584–94. doi:10.1056/NEJMsr1408795.
[19] K. Kupferschmidt. Study claiming new coronavirus can be transmitted by people without symptoms was flawed. Science, (2020),http://dx.doi.org/10.1126/science.abb1524.

[20] N. M. Ferguson et al., “Impact of non-pharmaceutical interventions (npis) to reduce covid-19 mortality and healthcare demand”, London: Imperial College COVID- 19 Response Team, March 16 (2020), 10.25561/77482.

Downloads

Published

2020-06-03

How to Cite

Das, D. P. K. (2020). A CRITICAL APPRAISAL OF COVID-19 IN INDIA. Archives of Business Research, 8(5), 227–235. https://doi.org/10.14738/abr.85.8271